Our extensive experience in health technology assessment (HTA) through providing strategic advice and guiding evidence generation to support submissions to UK HTA bodies, enables us to provide you with a tailored solution to reimbursement and patient access.
Real-World Comparator Evidence for BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer: Derivation of an NHS England Registry Cohort to Support Indirect Comparative Effectiveness Analyses.